✦ LIBER ✦

A phase I dose escalation study with anti-CD44V6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

✍ Scribed by R. De Bree; B.M. Tijink; J. Buter; G. Giaccone; M.S. Lang; A. Staab; C.R. Leemans; G.A.M.S. Van Dongen

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial with the CD44v6-targeting

✍ Herbert Riechelmann; Alexander Sauter; Wolfram Golze; Gertraud Hanft; Carsten Sc 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 522 KB

Cisplatin pharmacokinetics and pharmacod

✍ A. Johnsson; Peter Höglund; Anders Grubb; Eva Cavallin-Sta˚hl 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 781 KB

A phase I dose escalation study of Nimot

✍ Kuai-le Zhao, Xi-chun Hu, Xiang-hua Wu, Xiao-long Fu, Min Fan, Guo-Liang Jiang 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 215 KB

Erlotinib and bevacizumab in patients wi

✍ Ezra EW Cohen; Darren W Davis; Theodore G Karrison; Tanguy Y Seiwert; Stuart J W 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 442 KB

Phase II study of gefitinib adaptive dos

✍ Cesar A. Perez; Hunho Song; Luis E. Raez; Mark Agulnik; Tatyana A. Grushko; Alli 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 328 KB

A phase II study of docetaxel in patient

✍ Couteau, C; Chouaki, N; Leyvraz, S; Oulid-Aissa, D; Lebecq, A; Domenge, C; Groul 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 63 KB